Avacta Group’s (LSE:AVCT) oncology division, Avacta Therapeutics, continues to advance its proprietary pre|CISION drug delivery platform, which is designed to activate cancer therapies directly within tumours through Fibroblast Activation Protein (FAP)-mediated targeting. The approach aims to deliver highly potent chemotherapy agents more selectively to tumour tissue while reducing systemic side effects commonly associated with conventional antibody-drug conjugates (ADCs).
The company’s lead programme, AVA6000, has already demonstrated early signs of activity in selected solid tumour indications.
Comparative data positions platform against leading ADC therapies
During its 2026 Science Day event in London, Avacta presented new comparative data from its AVA6103 and AVA6207 programmes, highlighting the potential competitive advantages of the pre|CISION platform against established marketed ADCs.
According to the company, AVA6103 demonstrated significantly faster tumour penetration, higher concentrations of therapeutic payload within tumours and a tumour selectivity index at least three times greater than both Enhertu and Datroway.
Meanwhile, AVA6207’s dual-payload design produced deeper and more sustained responses than single-payload ADCs, including Enhertu, in gastric cancer and FAP-driven tumour models.
Intellectual property and differentiation strategy strengthened
The new data is expected to reinforce Avacta’s differentiation strategy within the rapidly growing oncology drug conjugate market. Management believes the platform’s tumour-selective activation technology could offer advantages in efficacy, tolerability and dosing flexibility compared with traditional ADC approaches.
The findings may also strengthen the company’s intellectual property position as it continues development across multiple oncology programmes.
Financial and partnership risks remain a concern
Despite scientific and clinical progress, Avacta’s broader outlook continues to be constrained by weak financial performance and bearish technical indicators.
The company remains loss-making and continues to face funding pressures, while the absence of major commercial partnerships is viewed as an additional risk factor. Valuation metrics also remain unattractive due to negative earnings and the lack of a dividend.
More about Avacta Group plc
Avacta Group plc is a clinical-stage biotechnology company focused on oncology through its Avacta Therapeutics division. The company develops cancer therapies using its proprietary pre|CISION platform, a FAP-activated drug delivery system designed to concentrate highly potent chemotherapies within the tumour microenvironment while limiting damage to healthy tissue. Its peptide drug conjugates represent a novel class of targeted therapies, with lead candidate AVA6000 focused on doxorubicin-sensitive solid tumours.
Leave a Reply